550 related articles for article (PubMed ID: 2874666)
1. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
3. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.
Dayer P; Gasser R; Gut J; Kronbach T; Robertz GM; Eichelbaum M; Meyer UA
Biochem Biophys Res Commun; 1984 Nov; 125(1):374-80. PubMed ID: 6508804
[TBL] [Abstract][Full Text] [Related]
5. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
7. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
[TBL] [Abstract][Full Text] [Related]
8. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.
Knodell RG; Dubey RK; Wilkinson GR; Guengerich FP
J Pharmacol Exp Ther; 1988 Jun; 245(3):845-9. PubMed ID: 3385644
[TBL] [Abstract][Full Text] [Related]
9. Oxidation of quinidine by human liver cytochrome P-450.
Guengerich FP; Müller-Enoch D; Blair IA
Mol Pharmacol; 1986 Sep; 30(3):287-95. PubMed ID: 3748010
[TBL] [Abstract][Full Text] [Related]
10. Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation.
Gut J; Meier UT; Catin T; Meyer UA
Biochim Biophys Acta; 1986 Dec; 884(3):435-47. PubMed ID: 3096378
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
12. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
13. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition.
Knodell RG; Hall SD; Wilkinson GR; Guengerich FP
J Pharmacol Exp Ther; 1987 Jun; 241(3):1112-9. PubMed ID: 3598900
[TBL] [Abstract][Full Text] [Related]
14. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
[TBL] [Abstract][Full Text] [Related]
15. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.
Relling MV; Aoyama T; Gonzalez FJ; Meyer UA
J Pharmacol Exp Ther; 1990 Jan; 252(1):442-7. PubMed ID: 2299601
[TBL] [Abstract][Full Text] [Related]
16. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1997 Jun; 281(3):1199-210. PubMed ID: 9190854
[TBL] [Abstract][Full Text] [Related]
17. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6.
Mautz DS; Nelson WL; Shen DD
Drug Metab Dispos; 1995 Apr; 23(4):513-7. PubMed ID: 7600921
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2.
Yasumori T; Murayama N; Yamazoe Y; Kato R
Clin Pharmacol Ther; 1990 Mar; 47(3):313-22. PubMed ID: 2311333
[TBL] [Abstract][Full Text] [Related]
19. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
20. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
Zanger UM; Vilbois F; Hardwick JP; Meyer UA
Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]